Unsaturated Hydroxamic Acid Derivatives and Their Use for the Treatment and Prevention of an Ammonia-Associated Disease or Disorder
US-2024293344-A1 · Sep 5, 2024 · US
US10543166B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10543166-B2 |
| Application number | US-82521510-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 28, 2010 |
| Priority date | Jun 26, 2009 |
| Publication date | Jan 28, 2020 |
| Grant date | Jan 28, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A drug delivery device is provided that includes a device body, a number of solid, compressed drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The number of solid, compressed drug tablets are positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen. The drug tablets may be mini-tablets aligned in the drug reservoir lumen, with an interstice formed between any two adjacent drug tablets facilitating deformation of the device body. Systems and method are also provided for loading a drug delivery device. In one embodiment, the method includes positioning one or more solid drug units upstream of the drug delivery device; and driving the drug units into the drug delivery device with a flow of pressurized gas.
Opening claim text (preview).
We claim: 1. An intravesical drug delivery device comprising: a device body comprising a drug reservoir lumen and a retention frame lumen; a plurality of solid drug units positioned in the drug reservoir lumen, each of the solid drug units being directly adjacent at least one other of the solid drug units; and a retention frame positioned in the retention frame lumen, wherein: the solid drug units have a selectively imparted shape, the solid drug units are cylindrical in shape, and the solid drug units have opposed flat ends. 2. An intravesical drug delivery device comprising: a device body comprising a drug reservoir lumen and a retention frame lumen; at least two solid, elongated drug tablets positioned end-to-end in the drug reservoir lumen, the drug tablets having a length:width aspect ratio greater than 1:1; and a retention frame positioned in the retention frame lumen, wherein the solid drug tablets have flat end faces and a cylindrical side face.
Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title
Local anaesthetics · CPC title
Anaesthetics · CPC title
of the bladder · CPC title
Tabletting processes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.